乳腺癌P-gp免疫组化染色对预测多药耐药的价值  

Pgp Immunohistochemical Analysis Predicts Multidrug Resistance in Breast Cancer

作　　者：程伏林[1] 杨国梁[1] 黄金求 冯茂辉[1] 

机构地区：[1]湖北医科大学附属第二医院肿瘤研究所

出　　处：《齐鲁肿瘤杂志》1997年第4期250-252,共3页

摘　　要：为了探索免疫组织化学技术在检测乳腺癌多药耐受表型中的价值，我们采用链霉菌抗生物素蛋白——过氧化物酶连结法（ＳＰ法）分析了６０例术前未经任何化学治疗的乳腺癌组织Ｐ－ｇｐ表达情况，１２例癌旁正常乳腺组织和８例乳腺良性肿瘤组织作为对照。结果发现：三种组织阳性率分别为：乳腺癌组７６．７％（４６／６０），癌旁正常乳腺组织１６．７％（２／１２），乳腺良性肿瘤２５．０％（２／８）。癌组织与其它两种组织相比，差异具有显著性（Ｐ＜０．００５）。并且，乳腺癌组织Ｐ－ｇｐ表达水平与提示乳腺癌疾病发展和预后的临床病理参数，如年龄、原发灶大小、淋巴结转移数、ＴＮＭ分期、病理学类型和组织学分级无关（Ｐ＞０．０５）。我们得出结论，多药耐受表型是与乳腺癌恶性表型同时发生的一种内在本质特征，并且其表达程度不受疾病发展的影响，Ｐ－ｇｐ免疫组化染色能够有效地检测乳腺癌多药耐受。We applied SP immunohistochemical technique to examine Pgp expression of tumor samples from 60 patients with primary breast cancer,who had not received any chemotherapy before surgery.12 normal breast tissues adjacent to cancer and 8 benign breast tumors were used as control.The results showed that a high Pgp positive rate (76.7%)was significantly present in the breast cancer group in comparison with the normal breast tissue's and the benign breast tumor's(16.75 and 25.05,respectively),and P-gp expression in breast cancer was not associated with any of the clinicopathological parameters such as age ,tumor size,axillary lymphonodus metastasis,clinical TNM stage,histologic type and tumor grade.Experimental data indicated that an intrinsic drug resistance existed in breast cancer.

关 键 词：乳腺癌 耐药 P-糖蛋白 化学疗法 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]